O'Shaughnessy Asset Management’s Ocular Therapeutix OCUL Stock Holding History

O'Shaughnessy Asset Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3,525	Closed	-$35K	–	2067
2021 Q3	$35K	Sell	3,525 -533	-13%	-$5.99K	﹤0.01%	1783
2021 Q2	$58K	Hold	4,058	–	–	﹤0.01%	1527
2021 Q1	$67K	Hold	4,058	–	–	﹤0.01%	1325
2020 Q4	$84K	Buy	4,058 +3,971	+4,564%	+$59K	﹤0.01%	1120
2020 Q3	$1K	Hold	87	–	–	﹤0.01%	1766
2020 Q2	$1K	Buy	+87	New	+$577	﹤0.01%	1633
2020 Q1	–	Sell	-87	Closed	–	–	1645
2019 Q4	$0	Buy	+87	New	+$302	﹤0.01%	1878

Other funds holding OCUL

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

O'Shaughnessy Asset Management's OCUL Position: Q4 2021 in Review

O'Shaughnessy Asset Management sold out of Ocular Therapeutix (OCUL) in Q4 2021, closing a stake of 3,525 shares — an estimated $35K sold.

O'Shaughnessy Asset Management first reported a position in OCUL in Q4 2019 and held it in 7 quarters. The position peaked at $84K in Q4 2020. 140 funds tracked by Wall St. Rank hold OCUL as of Q4 2021.

O'Shaughnessy Asset Management reported no remaining Ocular Therapeutix position as of Q4 2021 after selling out during the quarter.
O'Shaughnessy Asset Management sold 3,525 Ocular Therapeutix shares in Q4 2021, an estimated $35K.
O'Shaughnessy Asset Management first reported a position in Ocular Therapeutix in Q4 2019 and held it in 7 quarters.
O'Shaughnessy Asset Management's Ocular Therapeutix position peaked at $84K in Q4 2020.
140 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2021.

Based on O'Shaughnessy Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.